Santhera becomes Founding Member of the Industry Advisory Council of the United Mitochondrial Disease Foundation - Seite 2

Raxone^® is a trademark of Santhera Pharmaceuticals.     

About UMDF
Founded in 1996, the United Mitochondrial Disease Foundation (UMDF) works to promote research and education for the diagnosis, treatment and cure of mitochondrial diseases and to provide support for affected individuals and families. Since its inception, the UMDF has funded nearly USD 11 million in research, making it the leading non-governmental contributor of grants focused solely on mitochondrial disease. The UMDF, based in Pittsburgh, PA, is a US-national organization, represented around the world by thousands of members. For more information about mitochondrial disease or the UMDF, visit www.umdf.org.

For further information, contact:
Thomas Meier, PhD, Chief Executive Officer          Christoph Rentsch, Chief Financial Officer
Phone [phone]                                        Phone [phone]
[e-mail]                                [e-mail]

Sue Schneidhorst, Head Group Communications
Phone [phone]
[e-mail]

US investor contact                                             US Public Relations contact
Hans Vitzthum, LifeSci Advisors, LLC                    John Gillespie, Medical Dynamics
Phone [phone]                                         Phone [phone]
[e-mail]                                    [e-mail]

Disclaimer / Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.

# # #

News Release UMDF

---

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Santhera Pharmaceuticals Holding AG via Globenewswire

--- End of Message ---

Santhera Pharmaceuticals Holding AG
Hammerstrasse 49 Liestal Switzerland

ISIN: CH0027148649;